论文信息 - Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). - 字舞流文

Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).

Michael Thomas | R. Doebele | G. Curigliano | Dong-Wan Kim | D. Tan | Dae-Ho Lee | S. Gadgeel | B. Besse | G. Lopes | Matthew H Taylor | V. Subbiah | C. Baik | P. Cassier | Stephen V. Liu | C. Turner | J. Gainor | Hui Zhang | V. Zhu | C. Clifford | M. Palmer | Matthew H. Taylor